Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.

Published in: Journal of diabetes research (2022)

Liraglutide and dapagliflozin had strong hypoglycaemic effects in patients with overweight or obesity and T2DM at the beginning of the COVID-19 pandemic. Dapagliflozin may be beneficial in improving SBP and LDL-C levels; however, further research is warranted.

Keyphrases

weight loss
weight gain
glycemic control
clinical trial
insulin resistance
metabolic syndrome
type diabetes
high fat diet induced
body mass index
study protocol
physical activity
open label
phase ii
cardiovascular risk factors
adipose tissue
randomized controlled trial
cardiovascular disease
low density lipoprotein